EGFR and non-small cell lung carcinoma: The NSCLC cell line HCC4006 was adapted to the EGFR-TKIs afatinib (HCCrA), erlotinib (HCCrE), gefitinib (HCCrG), and osimertinib (HCCrO) by continuous exposure to increasing drug concentrations.